Every year brings its own distinct changes. For the life sciences industry, 2022 was marked by challenges such as the ongoing influence of the pandemic, a turbulent economy and a shrinking biotech bubble — along with positive momentum around DE&I and the continued integration of paradigm-shifting tech.
What will 2023 have in store? As we round the corner toward a New Year, PharmaVoice has cast its eyes to the future and asked its community of pharma leaders about what they see coming down the pipes.
In particular, we identified six key areas of focus for 2023: diversity in clinical trials, the hottest tech, cultivating innovation, talent management, patient engagement and leadership in uncertain times. There are connective tissues that weave throughout each of these large buckets, which is by no means an exhaustive list of all the issues facing the industry. Yet, they encompass the trends that are likely to make the biggest impact on pharma leaders’ strategic focus in the coming year.
We want to thank the dozens of industry thought leaders who contributed to this special feature. Stay tuned in January when we unveil our “crystal ball” outlook on various other trends that are expected to influence decision-making and resource allotment in the year to come.
For now, here’s a look at how industry leaders are navigating the key issues of 2023.